These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy. Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816 [TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286 [TBL] [Abstract][Full Text] [Related]
4. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts. Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864 [TBL] [Abstract][Full Text] [Related]
6. Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic. Di Stefano V; Lupica A; Alonge P; Pignolo A; Augello SM; Gentile F; Gagliardo A; Giglia F; Brinch D; Cappello M; Di Lisi D; Novo G; Borgione E; Scuderi C; Brighina F Eur J Neurol; 2024 Jan; 31(1):e16065. PubMed ID: 37725003 [TBL] [Abstract][Full Text] [Related]
7. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254 [TBL] [Abstract][Full Text] [Related]
8. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal. Ando Y; Waddington-Cruz M; Sekijima Y; Koike H; Ueda M; Konishi H; Ishii T; Coelho T Orphanet J Rare Dis; 2023 Oct; 18(1):323. PubMed ID: 37828588 [TBL] [Abstract][Full Text] [Related]
9. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder]. Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239 [TBL] [Abstract][Full Text] [Related]
10. [Neurological manifestations of ATTR amyloidosis]. Pernice HF; Hahn K Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967 [TBL] [Abstract][Full Text] [Related]
11. Electro-clinical presentation of hereditary transthyretin related amyloidosis when presenting as a polyneuropathy of unknown origin in northern France. Davion JB; Bocquillon P; Cassim F; Frezel N; Lacour A; Dhaenens CM; Maurage CA; Gibier JB; Hachulla E; Nguyen The Tich S; Defebvre L; Merle PE; Tard C Rev Neurol (Paris); 2021 Nov; 177(9):1160-1167. PubMed ID: 34253345 [TBL] [Abstract][Full Text] [Related]
12. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. Gertz M; Adams D; Ando Y; Beirão JM; Bokhari S; Coelho T; Comenzo RL; Damy T; Dorbala S; Drachman BM; Fontana M; Gillmore JD; Grogan M; Hawkins PN; Lousada I; Kristen AV; Ruberg FL; Suhr OB; Maurer MS; Nativi-Nicolau J; Quarta CC; Rapezzi C; Witteles R; Merlini G BMC Fam Pract; 2020 Sep; 21(1):198. PubMed ID: 32967612 [TBL] [Abstract][Full Text] [Related]